Morning Overview on MSN
An FDA-approved drug added five months of survival in tough breast cancer
Patients diagnosed with metastatic triple-negative breast cancer, one of the most aggressive and treatment-resistant forms of ...
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus ...
The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 ...
CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...
Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 ...
Please provide your email address to receive an email when new articles are posted on . Sacituzumab govitecan did not improve PFS in HR-positive, HER2-negative breast cancer after endocrine therapy.
MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates ...
MORRIS PLAINS, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, ...
Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based ...
The US Food and Drug Administration (FDA) approved a new indication for sacituzumab govitecan (Trodelvy, Gilead Sciences) today for patients with unresectable, locally advanced or metastatic hormone ...
2.1 Sacituzumab govitecan (Trodelvy, Gilead Sciences) has a marketing authorisation for 'the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results